6 results
- To asses the safety and toxicity of peri-ablative sorafenib given in doses of either 200 mg or 400 mg twice daily.- To asses the effect of perioperative sorafenib on the RFA induced mobilization of endothelial progenitor cells and cytokines…
To evaluate the efficacy and safety of BIBF 1120 in HCC patients without prior systemic treatment as compared to Sorafenib.
The revised aims of the SORCE trial are:1. Does up to three years of treatment with sorafenib increase DFS compared with placebo: a comparison of Arm C vs Arm A2. If the answer to question (i) is yes, does one year of sorafenib (Arm B) increase DFS…
The purpose of the study is to investigate the ability of MYL-1401H to evoke an immune response (immunogenicity) as compared to Neulasta® US. In addition, the effect of MYL-1401H on blood cells as compared to Neulasta® US will be investigated. The…
To perform a pre-study to assess the feasibility of DE-MRI to assess lesion size, transmurality and completeness of pulmonary vein isolation. The study will be performed to determine if and how DE-MRI can be used in a larger subsequent multicentre…
The purpose of the study is to investigate how quickly and to what extent MYL-1401H is absorbed and eliminated from the body (this is called pharmacokinetics) as compared to Neulasta® EU and US. It will also be investigated what the effect is of MYL…